NCT06267963View on ClinicalTrials.gov

A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

April 12, 2024

Study Completion Date

April 12, 2024

Conditions
Healthy Participants
Interventions
DRUG

Oral [14C]PF-07220060

A single oral dose of \[14C\]PF-07220060, will be administered as a liquid formulation in Cohort 1.

DRUG

Oral PF-07220060

A single oral dose of PF-07220060, will be administered as a liquid formulation in Cohort 2.

DRUG

IV [14C] PF-07220060

A single IV infusion of \[14C\]PF-07220060 will be administered in Cohort 2 at Tmax after the administration of the unlabeled oral dose.

Trial Locations (1)

9728 NZ

PRA Health Sciences, Groningen

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY